• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

波舒替尼成功治疗一名由慢性髓性白血病转化而来、疑似累及中枢神经系统的老年急性淋巴细胞白血病患者的经验。

Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia.

作者信息

Atilla Erden, Ataca Pinar, Ozyurek Elif, Erden Ilhan, Gurman Gunhan

机构信息

Department of Hematology, Ankara University School of Medicine, 06590 Ankara, Turkey.

Department of Radiology, Ankara University School of Medicine, 06590 Ankara, Turkey.

出版信息

Case Rep Hematol. 2015;2015:689423. doi: 10.1155/2015/689423. Epub 2015 Dec 1.

DOI:10.1155/2015/689423
PMID:26697241
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4678072/
Abstract

Managing the blast phase in chronic myeloid leukemia (CML) is challenging because limited data are available for elderly patients. The involvement of the central nervous system (CNS) increases the risk of a poor prognosis. Here, we present an elderly blast phase CML patient with suspected CNS involvement who was successfully treated with bosutinib.

摘要

治疗慢性髓性白血病（CML）的急变期具有挑战性，因为老年患者的相关数据有限。中枢神经系统（CNS）受累会增加预后不良的风险。在此，我们报告一例疑似CNS受累的老年CML急变期患者，该患者接受波舒替尼治疗成功。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/86eb5a45273c/CRIHEM2015-689423.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/a9dbcf839676/CRIHEM2015-689423.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/2b740d54c512/CRIHEM2015-689423.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/d11b6eb1d752/CRIHEM2015-689423.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/86eb5a45273c/CRIHEM2015-689423.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/a9dbcf839676/CRIHEM2015-689423.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/2b740d54c512/CRIHEM2015-689423.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/d11b6eb1d752/CRIHEM2015-689423.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73bf/4678072/86eb5a45273c/CRIHEM2015-689423.004.jpg

相似文献

1
Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia.波舒替尼成功治疗一名由慢性髓性白血病转化而来、疑似累及中枢神经系统的老年急性淋巴细胞白血病患者的经验。
Case Rep Hematol. 2015;2015:689423. doi: 10.1155/2015/689423. Epub 2015 Dec 1.
2
Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.伊马替尼治疗失败后晚期慢性髓性白血病患者接受博舒替尼（SKI-606）治疗期间的健康相关生活质量
Curr Med Res Opin. 2016 Aug;32(8):1325-34. doi: 10.1185/03007995.2016.1174108. Epub 2016 May 5.
3
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.与博舒替尼治疗慢性期慢性髓性白血病相关的不良事件管理：专家小组审查。
J Hematol Oncol. 2018 Dec 27;11(1):143. doi: 10.1186/s13045-018-0685-2.
4
Bosutinib for the treatment of chronic myeloid leukemia.博舒替尼用于治疗慢性髓性白血病。
Am J Health Syst Pharm. 2015 Mar 15;72(6):439-47. doi: 10.2146/ajhp140221.
5
Benefits and risks of ponatinib versus bosutinib following treatment failure of two prior tyrosine kinase inhibitors in patients with chronic phase chronic myeloid leukemia: a matching-adjusted indirect comparison.两种酪氨酸激酶抑制剂治疗失败的慢性期慢性髓性白血病患者中，ponatinib 与 bosutinib 的获益与风险：匹配调整间接比较。
Curr Med Res Opin. 2019 Mar;35(3):479-487. doi: 10.1080/03007995.2018.1510225. Epub 2018 Aug 24.
6
Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation.慢性粒细胞白血病伴中枢神经系统浸润，经中枢神经系统定向化疗后成功治疗，随后进行异基因干细胞移植。
Int J Hematol. 2018 Dec;108(6):640-646. doi: 10.1007/s12185-018-2511-6. Epub 2018 Aug 4.
7
Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.博舒替尼：一种用于慢性粒细胞白血病的第二代酪氨酸激酶抑制剂。
Ann Pharmacother. 2013 Dec;47(12):1703-11. doi: 10.1177/1060028013503124.
8
Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.施达赛用于治疗对甲磺酸伊马替尼耐药或不耐受的慢性髓性白血病和费城染色体阳性的急性淋巴细胞白血病。
Clin Cancer Res. 2008 Jan 15;14(2):352-9. doi: 10.1158/1078-0432.CCR-07-4175.
9
[Analysis of 30 cases of chronic myeloid leukemia with non-myeloid blast crisis].30例慢性髓性白血病非髓系原始细胞危象分析
Zhonghua Nei Ke Za Zhi. 1989 Dec;28(12):731-3, 768.
10
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.酪氨酸激酶抑制剂时代慢性髓性白血病急变期患者的预后因素及生存结果：477例患者的队列研究
Cancer. 2017 Nov 15;123(22):4391-4402. doi: 10.1002/cncr.30864. Epub 2017 Jul 25.

引用本文的文献

1
Leukostasis With Isolated Central Nervous System Involvement in Chronic Phase of Chronic Myelogenous Leukemia.慢性粒细胞白血病慢性期孤立性中枢神经系统受累的白细胞淤滞症
J Hematol. 2023 Aug;12(4):187-196. doi: 10.14740/jh1150. Epub 2023 Aug 8.
2
Bosutinib in chronic myeloid leukemia: patient selection and perspectives.博舒替尼治疗慢性髓性白血病：患者选择与展望
J Blood Med. 2018 Apr 10;9:43-50. doi: 10.2147/JBM.S129821. eCollection 2018.

本文引用的文献

1
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors.博舒替尼治疗对伊马替尼和其他酪氨酸激酶抑制剂耐药或不耐受的白血病患者的安全性和毒性管理。
Blood. 2014 Feb 27;123(9):1309-18. doi: 10.1182/blood-2013-07-513937. Epub 2013 Dec 17.
2
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.欧洲白血病网络关于慢性髓性白血病管理的建议：2013 年版。
Blood. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26.
3
How I treat older patients with ALL.
我如何治疗老年 ALL 患者。
Blood. 2013 Aug 22;122(8):1366-75. doi: 10.1182/blood-2012-07-379016. Epub 2013 May 14.
4
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.博舒替尼对比伊马替尼用于新诊断的慢性期慢性髓性白血病：来自 BELA 试验的结果。
J Clin Oncol. 2012 Oct 1;30(28):3486-92. doi: 10.1200/JCO.2011.38.7522. Epub 2012 Sep 4.
5
A disease risk index for patients undergoing allogeneic stem cell transplantation.异体干细胞移植患者的疾病风险指数。
Blood. 2012 Jul 26;120(4):905-13. doi: 10.1182/blood-2012-03-418202. Epub 2012 Jun 18.
6
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.博舒替尼对于伊马替尼、达沙替尼和/或尼洛替尼治疗失败后的慢性期慢性髓性白血病具有活性。
Blood. 2012 Apr 12;119(15):3403-12. doi: 10.1182/blood-2011-11-390120. Epub 2012 Feb 27.
7
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.博舒替尼（SKI-606）治疗对伊马替尼耐药或不耐受的慢性期费城染色体阳性慢性髓性白血病患者的安全性和疗效。
Blood. 2011 Oct 27;118(17):4567-76. doi: 10.1182/blood-2011-05-355594. Epub 2011 Aug 24.
8
Bosutinib.博舒替尼
Recent Results Cancer Res. 2010;184:119-27. doi: 10.1007/978-3-642-01222-8_9.
9
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.慢性髓性白血病：欧洲白血病网络概念与管理建议的更新
J Clin Oncol. 2009 Dec 10;27(35):6041-51. doi: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2.
10
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.达沙替尼可穿过血脑屏障，是治疗中枢神经系统费城染色体阳性白血病的有效疗法。
Blood. 2008 Aug 15;112(4):1005-12. doi: 10.1182/blood-2008-02-140665. Epub 2008 May 13.